NO20022086D0 - Antidiabetisk formulering og fremgangsmåte - Google Patents

Antidiabetisk formulering og fremgangsmåte

Info

Publication number: NO20022086D0
Authority: NO; Norway
Prior art keywords: antidiabetic; formulation; antidiabetic formulation
Prior art date: 1999-11-03

Application number

NO20022086A

Other languages

English (en)

Other versions

NO20022086L (no

Inventor

Beth Anne Piper

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

2002-05-02

Publication date

2002-05-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022086(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-02 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-05-02 Publication of NO20022086D0 publication Critical patent/NO20022086D0/no

2002-06-24 Publication of NO20022086L publication Critical patent/NO20022086L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

NO20022086A 1999-11-03 2002-05-02 Antidiabetisk formulering og fremgangsmåte NO20022086L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/432,465 US6586438B2 (en)	1999-11-03	1999-11-03	Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (en)	1999-11-03	2000-10-13	Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent

Publications (2)

Publication Number	Publication Date
NO20022086D0 true NO20022086D0 (no)	2002-05-02
NO20022086L NO20022086L (no)	2002-06-24

Family

ID=23716278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022086A NO20022086L (no)	1999-11-03	2002-05-02	Antidiabetisk formulering og fremgangsmåte

Country Status (34)

Country	Link
US (2)	US6586438B2 (no)
EP (1)	EP1253944A2 (no)
JP (2)	JP2003529551A (no)
KR (2)	KR20020050253A (no)
CN (3)	CN100386114C (no)
AR (1)	AR026355A1 (no)
AU (1)	AU781781B2 (no)
BG (2)	BG65850B1 (no)
BR (1)	BR0015295A (no)
CA (1)	CA2389931A1 (no)
CZ (2)	CZ304090B6 (no)
DE (1)	DE60038455T2 (no)
EE (1)	EE05210B1 (no)
ES (1)	ES2302702T3 (no)
GE (2)	GEP20053539B (no)
HK (1)	HK1045655A1 (no)
HU (1)	HUP0300642A3 (no)
IL (3)	IL149138A0 (no)
LT (1)	LT5025B (no)
LV (1)	LV12907B (no)
MX (1)	MXPA02004290A (no)
MY (2)	MY125118A (no)
NO (1)	NO20022086L (no)
NZ (1)	NZ552074A (no)
PL (1)	PL366112A1 (no)
RO (1)	RO123109B1 (no)
RU (1)	RU2276604C2 (no)
SK (1)	SK4992002A3 (no)
TN (2)	TNSN00207A1 (no)
TW (1)	TWI241185B (no)
UA (2)	UA75583C2 (no)
UY (1)	UY26425A1 (no)
WO (1)	WO2001032158A2 (no)
ZA (2)	ZA200203368B (no)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
MXPA02009130A (es) *	2000-03-17	2003-03-12	Ajinomoto Kk	Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) *	2001-01-17	2006-06-13	Pediamed Pharmaceuticals, Inc.	Combination and method including a visual marker for determining compliance with a medication regimen
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) *	2001-05-23	2005-04-15	Flamel Tech Sa	Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003026637A2 (en) *	2001-09-28	2003-04-03	Sun Pharmaceutical Industries Limited	Dosage form for treatment of diabetes mellitus
US6924311B2 (en) *	2001-10-17	2005-08-02	X-Ceptor Therapeutics, Inc.	Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
DE60219963T2 (de)	2002-01-25	2008-02-07	Laboratorios Silanes, S.A. De C.V.	Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird
DE60325709D1 (de)	2002-04-09	2009-02-26	Flamel Tech Sa	Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
PL376577A1 (pl)	2002-06-17	2006-01-09	Themis Laboratories Private Limited	Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
ES2327328T3 (es) *	2002-07-04	2009-10-28	Zealand Pharma A/S	Glp-1 y procedimientos para el tratamiento de la diabetes.
JP2004067575A (ja) *	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) *	2002-08-26	2005-11-22	Indevex Ab	Födoämneskompositionsprodukt
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) *	2003-01-29	2004-07-29	Rao Vinay U.	Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
US20060134206A1 (en) *	2003-07-24	2006-06-22	Iyer Eswaran K	Oral compositions for treatment of diseases
ATE433994T1 (de) *	2003-07-25	2009-07-15	Conjuchem Biotechnologies Inc	Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
US20050202063A1 (en) *	2003-08-26	2005-09-15	Ebn International Kft	Food product
WO2005065663A1 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Rosiglitazone and metformin formulations
EP1732513A2 (en) *	2003-12-31	2006-12-20	Alpharma, Inc.	Rosiglitazone formulations
WO2005107750A1 (en) *	2004-04-29	2005-11-17	Andrx Labs. Llc	Controlled release metformin compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006074278A2 (en) *	2005-01-05	2006-07-13	Mitsunori Ono	Compositions for treating diabetes or obesity
CN101111266A (zh) *	2005-01-31	2008-01-23	味之素株式会社	含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
EP1889618A4 (en) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
AU2006326658A1 (en) *	2005-12-09	2007-06-21	Metaproteomics, Llc	Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
GEP20105033B (en) *	2005-12-28	2010-06-25	Takeda Pharmaceuticals Co	Therapeutic agent for diabetes
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CA2659012A1 (en) *	2006-07-26	2008-01-31	Diamedica Inc.	Methods of diagnosis and treatment for metabolic disorders
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) *	2008-05-16	2010-06-03	Interleukin Genetics, Inc.	Genetic Markers for Weight Management and Methods of Use Thereof
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
SMT201700416T1 (it)	2009-03-31	2017-11-15	Ligand Pharm Inc	Antagonista di bifenilsolfonammide del recettore di endotelina ed angiotensina ii per il trattamento della glomerulosclerosi
SG10201605794PA (en)	2009-04-29	2016-09-29	Amarin Pharmaceuticals Ie Ltd	Stable Pharmaceutical Composition And Methods Of Using Same
RU2624506C2 (ru)	2009-04-29	2017-07-04	АМАРИН КОРПОРЕЙШН ПиЭлСи	Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения
DK3318255T3 (da)	2009-06-15	2021-06-07	Amarin Pharmaceuticals Ie Ltd	Sammensætninger og fremgangsmåder til behandling af slagtilfælde hos en patient på samtidig statin-terapi
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
CN102753161A (zh)	2009-11-27	2012-10-24	贝林格尔.英格海姆国际有限公司	基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN101810628B (zh) *	2010-04-13	2012-05-23	北京四环科宝制药有限公司	二甲双胍格列吡嗪片及其制备方法
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
HUE029853T2 (en)	2010-05-11	2017-04-28	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ757815A (en)	2010-11-29	2020-05-29	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) *	2010-12-29	2012-07-05	Nutracryst Therapeutics Private Limited	Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
LT2661266T (lt)	2011-01-07	2020-12-10	Anji Pharma (Us) Llc	Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
JP6359972B2 (ja)	2011-11-03	2018-07-18	ジーランドファーマアクティーゼルスカブ	Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
CN110693867A (zh)	2012-01-06	2020-01-17	埃尔舍利克斯治疗公司	用于治疗代谢性病症的组合物和方法
KR20200137035A (ko)	2012-01-06	2020-12-08	앤지 파마 유에스 엘엘씨	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
WO2013115742A1 (en) *	2012-01-31	2013-08-08	Mahmut Bilgic	Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en)	2012-06-04	2017-05-22	Diamedica Inc	Kallikrein-1-glycosylation isoforms of human tissue
JP6534927B2 (ja)	2012-07-23	2019-06-26	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) *	2013-03-06	2013-12-03	씨제이제일제당 (주)	당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
EA034322B1 (ru)	2013-10-17	2020-01-28	Зилэнд Фарма А/С	Ацилированные аналоги глюкагона
BR112016009889B1 (pt)	2013-11-06	2023-11-28	Zealand Pharma A/S	Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
TWI707867B (zh)	2015-04-16	2020-10-21	丹麥商西蘭製藥公司	醯化之昇糖素類似物
JP2019517542A (ja)	2016-06-10	2019-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	リナグリプチンおよびメトホルミンの組合せ
EP3551651B1 (en)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
US11857608B2 (en)	2017-03-09	2024-01-02	Diamedica Inc.	Dosage forms of tissue kallikrein 1
AU2018326705A1 (en)	2017-08-30	2020-03-05	Pendulum Therapeutics, Inc.	Methods and compositions for treatment of microbiome-associated disorders
GB2593600A (en) *	2018-09-24	2021-09-29	Pendulum Therapeutics Inc	Microbial compositions and methods of use
KR20240135078A (ko)	2018-09-24	2024-09-10	애머린 파마슈티칼스 아일랜드 리미티드	대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CN113648318B (zh) *	2020-05-12	2023-08-25	中国科学院上海营养与健康研究所	增强细胞产热和治疗疾病的应用
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE2348334C2 (de)	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en)	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de)	1980-12-03	1982-10-20	Hoechst Aktiengesellschaft	Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4916163A (en)	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de)	1988-10-01	1991-09-12	Hoechst Ag	Verfahren zur mikronisierung von glibenclamid
US5258185A (en) *	1989-08-23	1993-11-02	Bauer Kurt H	Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DE4323636A1 (de)	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it)	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
EP0998271B3 (en) *	1997-06-06	2014-10-29	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
PT1011673E (pt)	1997-06-13	2001-11-30	Novo Nordisk As	Nova posologia para a dmni
CN1114404C (zh)	1997-06-18	2003-07-16	史密丝克莱恩比彻姆有限公司	用噻唑烷二酮和二甲双胍治疗糖尿病
GB9715306D0 (en)	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
EP1030665A4 (en)	1997-10-17	2002-11-27	Aventis Pharm Prod Inc	THERAPEUTIC USE OF CHINOLINE DERIVATIVES
JP4278863B2 (ja)	1997-12-08	2009-06-17	ブリストル−マイヤーズスクイブカンパニー	メトホルミンの新規塩および方法
FR2774591B1 (fr)	1998-02-12	2000-05-05	Lipha	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) *	1998-02-24	2003-06-13	Kemira Chemicals Oy	Menetelmä lietteen säilyvyyden parantamiseksi
JP2002508162A (ja)	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
DK0974356T3 (da)	1998-07-15	2003-10-27	Merck Sante Sas	Tabletter omfattende en kombination af metformin og glibenclamid
AU754488B2 (en)	1998-09-17	2002-11-14	Bristol-Myers Squibb Company	Method for treating diabetes employing an aP2 inhibitor and combination
AR028299A1 (es)	1999-09-17	2003-05-07	Novartis Ag	Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP2620443A1 (en)	2012-01-25	2013-07-31	Galecto Biotech AB	Novel galactoside inhibitors of galectins

1999
- 1999-11-03 US US09/432,465 patent/US6586438B2/en not_active Expired - Lifetime
- 1999-12-14 US US09/460,920 patent/US7598262B2/en not_active Expired - Lifetime
2000
- 2000-10-13 MX MXPA02004290A patent/MXPA02004290A/es not_active Application Discontinuation
- 2000-10-13 PL PL00366112A patent/PL366112A1/xx not_active Application Discontinuation
- 2000-10-13 WO PCT/US2000/028467 patent/WO2001032158A2/en active IP Right Grant
- 2000-10-13 UA UA2002054481A patent/UA75583C2/uk unknown
- 2000-10-13 CN CNB008180288A patent/CN100386114C/zh not_active Expired - Lifetime
- 2000-10-13 GE GE4802A patent/GEP20053539B/en unknown
- 2000-10-13 GE GE4798A patent/GEP20053538B/en unknown
- 2000-10-13 DE DE60038455T patent/DE60038455T2/de not_active Expired - Lifetime
- 2000-10-13 CN CN2011101796999A patent/CN102283853A/zh active Pending
- 2000-10-13 EP EP00970913A patent/EP1253944A2/en not_active Withdrawn
- 2000-10-13 AU AU80229/00A patent/AU781781B2/en not_active Ceased
- 2000-10-13 RU RU2002113764/15A patent/RU2276604C2/ru not_active IP Right Cessation
- 2000-10-13 JP JP2001534363A patent/JP2003529551A/ja active Pending
- 2000-10-13 NZ NZ552074A patent/NZ552074A/en not_active IP Right Cessation
- 2000-10-13 KR KR1020027005677A patent/KR20020050253A/ko not_active Application Discontinuation
- 2000-10-13 UA UA2002054480A patent/UA76706C2/uk unknown
- 2000-10-13 ES ES00972122T patent/ES2302702T3/es not_active Expired - Lifetime
- 2000-10-13 HU HU0300642A patent/HUP0300642A3/hu unknown
- 2000-10-13 CZ CZ20021546A patent/CZ304090B6/cs not_active IP Right Cessation
- 2000-10-13 EE EEP200200241A patent/EE05210B1/xx not_active IP Right Cessation
- 2000-10-13 CZ CZ20021547A patent/CZ20021547A3/cs unknown
- 2000-10-13 SK SK499-2002A patent/SK4992002A3/sk not_active Application Discontinuation
- 2000-10-13 CA CA002389931A patent/CA2389931A1/en not_active Abandoned
- 2000-10-13 RO ROA200200560A patent/RO123109B1/ro unknown
- 2000-10-13 KR KR1020027005673A patent/KR100769786B1/ko not_active Expired - Lifetime
- 2000-10-13 IL IL14913800A patent/IL149138A0/xx active IP Right Grant
- 2000-10-13 BR BR0015295-1A patent/BR0015295A/pt not_active Application Discontinuation
- 2000-10-13 CN CN2008100817553A patent/CN101273981B/zh not_active Expired - Lifetime
- 2000-10-24 MY MYPI20004996A patent/MY125118A/en unknown
- 2000-10-24 MY MYPI20004995A patent/MY136636A/en unknown
- 2000-10-27 TN TNTNSN00207A patent/TNSN00207A1/en unknown
- 2000-10-27 TN TNTNSN00206A patent/TNSN00206A1/en unknown
- 2000-10-27 TW TW089122629A patent/TWI241185B/zh not_active IP Right Cessation
- 2000-11-02 UY UY26425A patent/UY26425A1/es unknown
- 2000-11-03 AR ARP000105804A patent/AR026355A1/es unknown
2002
- 2002-04-15 IL IL149138A patent/IL149138A/en not_active IP Right Cessation
- 2002-04-15 IL IL149139A patent/IL149139A/en active IP Right Grant
- 2002-04-26 ZA ZA200203368A patent/ZA200203368B/xx unknown
- 2002-04-26 ZA ZA200203367A patent/ZA200203367B/xx unknown
- 2002-05-02 NO NO20022086A patent/NO20022086L/no unknown
- 2002-05-22 BG BG106733A patent/BG65850B1/bg unknown
- 2002-05-22 BG BG106732A patent/BG106732A/bg unknown
- 2002-05-24 LT LT2002062A patent/LT5025B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-93A patent/LV12907B/en unknown
- 2002-09-30 HK HK02107208.1A patent/HK1045655A1/zh unknown
2012
- 2012-09-25 JP JP2012211400A patent/JP2013028631A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
UY26425A1 (es)	2001-07-31
IL149139A (en)	2011-11-30
TNSN00207A1 (en)	2005-11-10
JP2003529551A (ja)	2003-10-07
LV12907B (en)	2003-08-20
WO2001032158A3 (en)	2002-08-29
BR0015295A (pt)	2003-06-24
MY136636A (en)	2008-11-28
EE05210B1 (et)	2009-10-15
IL149138A0 (en)	2002-11-10
CN102283853A (zh)	2011-12-21
AR026355A1 (es)	2003-02-05
NO20022086L (no)	2002-06-24
BG65850B1 (bg)	2010-03-31
AU781781B2 (en)	2005-06-16
BG106733A (bg)	2003-02-28
KR20020057994A (ko)	2002-07-12
HUP0300642A3 (en)	2006-05-29
UA75583C2 (uk)	2006-05-15
HK1045655A1 (zh)	2002-12-06
HUP0300642A2 (hu)	2003-07-28
TWI241185B (en)	2005-10-11
US6586438B2 (en)	2003-07-01
CN1414862A (zh)	2003-04-30
JP2013028631A (ja)	2013-02-07
US20020177602A1 (en)	2002-11-28
LT2002062A (en)	2003-03-25
DE60038455D1 (de)	2008-05-08
RO123109B1 (ro)	2010-11-30
CZ20021547A3 (cs)	2003-01-15
MXPA02004290A (es)	2003-02-12
AU8022900A (en)	2001-05-14
KR100769786B1 (ko)	2007-10-24
ZA200203367B (en)	2003-09-10
TNSN00206A1 (en)	2005-11-10
ES2302702T3 (es)	2008-08-01
DE60038455T2 (de)	2009-04-23
CN101273981B (zh)	2011-01-26
UA76706C2 (uk)	2006-09-15
CZ304090B6 (cs)	2013-10-16
LT5025B (lt)	2003-06-25
CN101273981A (zh)	2008-10-01
NZ552074A (en)	2008-06-30
US20020183345A1 (en)	2002-12-05
CA2389931A1 (en)	2001-05-10
IL149138A (en)	2007-12-03
RU2276604C2 (ru)	2006-05-20
GEP20053538B (en)	2005-06-10
ZA200203368B (en)	2003-09-02
SK4992002A3 (en)	2003-04-01
KR20020050253A (ko)	2002-06-26
WO2001032158A2 (en)	2001-05-10
CN100386114C (zh)	2008-05-07
RU2002113764A (ru)	2004-03-20
MY125118A (en)	2006-07-31
US7598262B2 (en)	2009-10-06
BG106732A (bg)	2003-02-28
GEP20053539B (en)	2005-06-10
PL366112A1 (en)	2005-01-24
EP1253944A2 (en)	2002-11-06
EE200200241A (et)	2003-12-15

Publication	Publication Date	Title
NO20022086D0 (no)	2002-05-02	Antidiabetisk formulering og fremgangsmåte
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
DK1454907T3 (da)	2009-03-09	Quninazolin og pyridopyrmidin-derivativer
NO20022334L (no)	2002-07-09	Ny sammensetning og anvendelse
NO20032753D0 (no)	2003-06-17	Forbindelse og anvendelse derav
DE60044764D1 (de)	2010-09-16	Durchgangs -Vorrichtung und -Verfahren
DE60031119D1 (de)	2006-11-16	Richtbohrvorrichtung und -verfahren
ATE311741T1 (de)	2005-12-15	Ernteverfahren und erntevorrichtung
DK1339292T3 (da)	2010-04-12	Sammensætning og fremgangsmåde
DE60014208D1 (de)	2004-11-04	Druckvorrichtung und -verfahren
DE50010609D1 (de)	2005-07-28	Sport-trainings-vorrichtung sowie sport-trainings-system
EP1455793A4 (en)	2007-03-07	ANTI-DIABETAL FORMULATION AND METHOD
NO20001485D0 (no)	2000-03-22	Redigeringsanordning og redigeringsfremgangsmåte
NO20002584D0 (no)	2000-05-19	Brønnreferanseapparat og fremgangsmÕte
NO20000188D0 (no)	2000-01-14	Fremgangsmåte og anordning for sidebroenntilknytning
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
NO20016132L (no)	2001-12-14	Fremgangsmåte og anordning for batterier
DE60001791D1 (de)	2003-04-30	Bilderzeugungsgerät und -Verfahren
DE60028676D1 (de)	2006-07-27	Positionierungsverfahren und Positionierungsvorrichtung
DE60014484D1 (de)	2004-11-11	Anreiss-Vorrichtung und -Verfahren
NO20005763L (no)	2001-01-10	DHEA-sammensetning og fremgangsmåte
FI19991928L (fi)	2001-03-10	Punnitusmenetelmä ja -järjestely
NO20003268D0 (no)	2000-06-22	Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
DE60041297D1 (de)	2009-02-26	Empfangsgerät und- Verfahren
IT1316669B1 (it)	2003-04-24	Dispositivo di azionamento ed impostazione